---
title: "Lyra Therapeutics, Inc. (LYRA.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/LYRA.US.md"
symbol: "LYRA.US"
name: "Lyra Therapeutics, Inc."
industry: "Pharmaceuticals"
---

# Lyra Therapeutics, Inc. (LYRA.US)

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Location | US Market |
| Website | [lyratherapeutics.com](https://lyratherapeutics.com) |

## Company Profile

Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of anti-inflammatory therapies for the treatment of patients with chronic rhinosinusitis. Its technology is designed to deliver medicines directly to the affected tissue for sustained pe...

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-21T04:30:15.000Z

**Overall: E (0.89)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 189 / 190 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -59.21% |  |
| Net Profit YoY | 66.25% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | -0.59 |  |
| Dividend Ratio | 0.00% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 2.57M |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 600000.00 |  |


**Multi Score**: E

#### Profit Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -404.48% | E |
| Profit Margin | -5491.17% | E |
| Gross Margin | -16088.00% | E |

#### Growth Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -59.21% | E |
| Net Profit YoY | 66.25% | A |
| Total Assets YoY | -44.50% | E |
| Net Assets YoY | -120.99% | E |

#### Cash Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | -1.82% | D |
| OCF YoY | -59.21% | E |

#### Operating Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.01 | E |

#### Debt Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 109.90% | E |


```chart-data:radar
{
  "title": "Longbridge Financial Score - Lyra Therapeutics, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "E",
      "indicators": [
        {
          "name": "ROE",
          "value": "-404.48%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-5491.17%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "-16088.00%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "E",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-59.21%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "66.25%",
          "rating": "A"
        },
        {
          "name": "Total Assets YoY",
          "value": "-44.50%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-120.99%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "D",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "-1.82%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "-59.21%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "E",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.01",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "E",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "109.90%",
          "rating": "E"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | Eli Lilly (US.LLY) | A | A | B | E | B | B |
| 02 | ROCHE HOLDINGS AG (US.RHHVF) | A | B | B | D | C | B |
| 03 | Roche (US.RHHBY) | A | B | B | D | C | B |
| 04 | AstraZeneca (US.AZN) | A | B | C | D | C | B |
| 05 | NOVARTIS AG (US.NVS) | A | B | C | D | C | B |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -0.08 | 65/257 | - | - | - |
| PB | -0.59 | 202/257 | 6.69 | 3.58 | 0.69 |
| PS (TTM) | 4.29 | 87/257 | 13.71 | 10.35 | 5.51 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-01-30T05:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 0 | 0% |
| Overweight | 0 | 0% |
| Hold | 1 | 100% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 1.45 |
| Highest Target | 16.00 |
| Lowest Target | 16.00 |

## References

- [Company Overview](https://longbridge.com/en/quote/LYRA.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/LYRA.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/LYRA.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.